Press Releases | PTC Therapeutics, Inc.

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Year

Sep 09, 2014

PTC THERAPEUTICS COMPLETES ENROLLMENT OF LANDMARK TRIAL IN DUCHENNE MUSCULAR DYSTROPHY

- Top-line data expected H2 2015- -Data intended to support applications for additional approvals globally

Aug 20, 2014

PTC THERAPEUTICS TO PARTICIPATE AT UPCOMING INVESTOR CONFERENCES

PTC THERAPEUTICS TO PARTICIPATE AT UPCOMING INVESTOR CONFERENCES SOUTH PLAINFIELD, NJ – August 20, 2014 –PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it will participate at two upcoming investor conferences: FBR 1st Annual Healthcare Conference at the Four Seasons Hotel in Boston on

Aug 07, 2014

PTC Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update

-Conference Call Today at 8:30 am ET-

Aug 07, 2014

Orally delivered compounds, which selectively modify RNA splicing prevent deficits in mouse models of Spinal Muscular Atrophy

-Results published in Science show small molecule SMN2 splicing modifiers to be effective in SMA mouse models-

Aug 04, 2014

PTC Therapeutics Receives Conditional Approval in the European Union for Translarna For the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy

- The first treatment approved for DMD

Aug 01, 2014

PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635©(4)

SOUTH PLAINFIELD, N.J., AUGUST 1, 2014 -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on July 31, 2014 it approved non-statutory stock options to purchase an aggregate of 67,700 shares of its common stock to seven new employees. The awards were made pursuant to the NASDAQ

Jul 30, 2014

PTC Therapeutics to Present at the Wedbush Life Sciences Management Access Conference

SOUTH PLAINFIELD, NJ – July 30, 2014 –PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the Wedbush Life Sciences Management Access Conference on Tuesday, August 12th at 4:15 pm ET at the Le Parker Meridien in New York City.

Jul 24, 2014

PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2014 Financial Results

SOUTH PLAINFIELD, NJ – July 24, 2014 – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2014 financial results and provide an update on the company's business and outlook on Thursday, August 7, 2014 at 8:30

Jul 09, 2014

PTC Therapeutics Announces Expanded Access Program For Translarna (ataluren)

-French ATU Cohort and Other Named Patient Programs Authorized -

Jun 30, 2014

PTC THERAPEUTICS RECIPIENT OF PARENT PROJECT MUSCULAR DYSTROPHY'S "PATH TO PROGRESS" AWARD

PTC THERAPEUTICS RECIPIENT OF PARENT PROJECT MUSCULAR DYSTROPHY'S "PATH TO PROGRESS" AWARD SOUTH PLAINFIELD, NJ June 30, 2014 PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that it is the recipient of Parent Project Muscular Dystrophy's (PPMD) "Path to Progress" award, honoring

Pagination

First page
Previous page
…
Page 47
Page 48
Current page 49
Page 50
Page 51
…
Next page
Last page